Literature DB >> 11197347

Molecular determinants of non-specific recognition of delta, mu, and kappa opioid receptors.

M Filizola1, H O Villar, G H Loew.   

Abstract

Identification of the molecular determinants of recognition common to all three opioid receptors embedded in a single three-dimensional (3D) non-specific recognition pharmacophore has been carried out. The working hypothesis that underlies the computational study reported here is that ligands that bind with significant affinity to all three cloned opioid receptors, delta, mu, and kappa, but with different combinations of activation and inhibition properties at these receptors, could be promising behaviorally selective analgesics with diminished side effects. The study presented here represents the first step towards the rational design of such therapeutic agents. The common 3D pharmacophore developed for recognition of delta, mu, and kappa opioid receptors was based on the receptor affinities determined for 23 different opioid ligands that display no specificity for any of the receptor subtypes. The pharmacophore centers identified are a protonated amine, two hydrophobic groups, and the centroid of an aromatic group in a geometric arrangement common to all 23, non-specific, opioid ligands studied. Using this three-dimensional pharmacophore as a query for searching 3D structural databases, novel compounds potentially involved in non-specific recognition of delta, mu, and kappa opioid receptors were retrieved. These compounds can be valuable candidates for novel behaviorally selective analgesics with diminished or no side effects, and thus with potential therapeutic usefulness.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11197347     DOI: 10.1016/s0968-0896(00)00223-6

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  9 in total

1.  Differentiation of delta, mu, and kappa opioid receptor agonists based on pharmacophore development and computed physicochemical properties.

Authors:  M Filizola; H O Villar; G H Loew
Journal:  J Comput Aided Mol Des       Date:  2001-04       Impact factor: 3.686

2.  Exploring the structure of opioid receptors with homology modeling based on single and multiple templates and subsequent docking: a comparative study.

Authors:  Indrani Bera; Aparna Laskar; Nanda Ghoshal
Journal:  J Mol Model       Date:  2010-07-27       Impact factor: 1.810

Review 3.  Homology modeling of opioid receptor-ligand complexes using experimental constraints.

Authors:  Irina D Pogozheva; Magdalena J Przydzial; Henry I Mosberg
Journal:  AAPS J       Date:  2005-10-05       Impact factor: 4.009

4.  Consensus 3D model of μ-opioid receptor ligand efficacy based on a quantitative Conformationally Sampled Pharmacophore.

Authors:  Jihyun Shim; Andrew Coop; Alexander D MacKerell
Journal:  J Phys Chem B       Date:  2011-05-12       Impact factor: 2.991

5.  Modeling and simulation of the human delta opioid receptor.

Authors:  Mahalaxmi Aburi; Paul E Smith
Journal:  Protein Sci       Date:  2004-07-06       Impact factor: 6.725

Review 6.  Pharmacokinetic and pharmacodynamic considerations in developing a response to the opioid epidemic.

Authors:  Rajiv Balyan; David Hahn; Henry Huang; Vidya Chidambaran
Journal:  Expert Opin Drug Metab Toxicol       Date:  2020-02-24       Impact factor: 4.481

7.  Pharmacological profiles of opioid ligands at kappa opioid receptors.

Authors:  Parham Gharagozlou; Ezzat Hashemi; Timothy M DeLorey; J David Clark; Jelveh Lameh
Journal:  BMC Pharmacol       Date:  2006-01-25

8.  Activation profiles of opioid ligands in HEK cells expressing delta opioid receptors.

Authors:  Parham Gharagozlou; Hasan Demirci; J David Clark; Jelveh Lameh
Journal:  BMC Neurosci       Date:  2002-11-18       Impact factor: 3.288

9.  Activity of opioid ligands in cells expressing cloned mu opioid receptors.

Authors:  Parham Gharagozlou; Hasan Demirci; J David Clark; Jelveh Lameh
Journal:  BMC Pharmacol       Date:  2003-01-04
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.